A press release from Leo Pharma described that delgocitinib cream qualified the primary endpoint in the DELTA 1 pivotal phase 3 clinical trial for treating moderate to severe chronic hand eczema (CHE) in adults.

It was tested in a randomized, double-blind, vehicle-controlled, multicenter trial, including 487 participants with moderate to severe CHE, where it showed a significant improvement in CHE after 16 weeks of treatment compared with vehicle. It cleared all or most of the CHE signs and symptoms early in the treatment period in a significantly larger proportion of patients than a vehicle.

Furthermore, most adverse events were nonserious, mild or moderate and unrelated to the treatment. It may emerge as a promising therapy for CHE.

Delgocitinib cream for CHE is further being investigated in the ongoing DELTA 2 trial, and the analysis of the DELTA 1 data will continue.

Source: Healio [Internet]. Positive phase 3 results reported for delgocitinib cream for chronic hand eczema. December 16, 2022. Available from: https://www.healio.com/news/dermatology/20221216/positive-phase-3-results-reported-for-delgocitinib-cream-for-chronic-hand-eczema